trending Market Intelligence /marketintelligence/en/news-insights/trending/mNKX26hmPcOvwfEbPx2Kig2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Takeda buys Cour Pharmaceutical's investigational autoimmune disorder drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Takeda buys Cour Pharmaceutical's investigational autoimmune disorder drug

Takeda Pharmaceutical Co. Ltd. exercised its option to acquire the exclusive license to develop and commercialize CNP-101, Cour Pharmaceutical Development Co. Inc.'s investigational autoimmune disorder drug.

CNP-101, also known as TAK-101, is being developed to treat celiac disease — a disorder in which eating gluten, or protein found in certain grains, elicits an immune response in a patient, causing inflammation and damage to the small intestine.

Under the deal, Northbrook, Ill.-based Cour Pharmaceutical will receive up to $420 million in future payments, along with royalties on sales of any products commercialized from the license.

Japan's Takeda and Cour Pharmaceutical initially agreed to jointly develop the medicine in 2015.

In the 2015 agreement, Takeda was granted an option to acquire the exclusive license following the completion of a phase 2a clinical study. Results from the mid-stage trial — which supported the Japanese drugmaker's decision to exercise its option showed that patients had well-controlled biopsy proven celiac disease after receiving the experimental treatment.

Takeda will advance the clinical development program of TAK-101 by conducting a dose-ranging in celiac disease patients who are on a gluten-free diet.